Anti-diabetic effects of puerarin, isolated from Pueraria lobata (Willd.), on streptozotocin-diabetogenic mice through promoting insulin expression and ameliorating metabolic function.
Diabetes is a chronic disease characterized by the metabolic disorder in specific tissues. Our present study was designed to assess the potential benefits of puerarin (PR) on hypoglycemic and hypolipemic effects in diabetic mice induced by streptozotocin (STZ). The results achieved from these experiments showed that glycemia in STZ-diabetogenic mice were significantly reduced following the PR administration, while serum insulin concentration was increased. In addition, PR contributed to improving the dyslipidemia conditions. Histopathological examination indicated that the STZ-lesioned pancreas tissue in PR-administrated mice was effectively alleviated. Meanwhile, intrapancreatic protein levels of insulin receptor substrate-1 (IRS-1) and insulin-like growth factor-1 (IGF-1) were up-regulated, respectively. On the other hand, endogenous mRNA levels of skeletal muscle insulin receptor (InsR) and peroxisome proliferators-activated receptor α (PPARα) were increased after administration of PR. Taken together, these findings reveal that puerarin effectively exerts the hypoglycemic and hypolipemic roles, which its potential anti-diabetic activity is associated with elevating insulin expression and maintaining metabolic homoeostasis in STZ-diabetogenic mice.
Department of Pharmacy, The Second People's Hospital of Nanning City, The Third Affiliated Hospital of Guangxi Medical University, Guangxi, Nanning 530031, PR China.
Ka
K
Wu
Tao
T
Liang
Xiaoqun
X
Duan
Lingyuan
L
Xu
Kefeng
K
Zhang
Rong
R
Li
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D005215:Fasting; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D055504:Insulin Receptor Substrate Proteins / Q000235:genetics / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000378:metabolism; D007529:Isoflavones / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D046529:Microscopy, Electron, Transmission; D018482:Muscle, Skeletal / Q000187:drug effects; D047493:PPAR alpha / Q000235:genetics / Q000378:metabolism; D010936:Plant Extracts / Q000494:pharmacology*; D029908:Pueraria / Q000737:chemistry*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D015854:Up-Regulation
D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007004:Hypoglycemic Agents; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; C526295:Irs1 protein, mouse; D007529:Isoflavones; D047493:PPAR alpha; D010936:Plant Extracts; D012333:RNA, Messenger; D014280:Triglycerides; C519530:insulin-like growth factor-1, mouse; D007334:Insulin-Like Growth Factor I; C033607:puerarin
Diabetes; FBG; FNS; Glycemia; ISI; Insulin; Metabolism; Puerarin; fasting blood-glucose; fasting serum insulin; insulin sensitivity index